DermTech, Inc (DMTK)

Etorro trading 970x250
DermTech, Inc (DMTK) Logo

About DermTech, Inc

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California. Address: 11099 North Torrey Pines Road, La Jolla, CA, United States, 92037

DermTech, Inc News and around…

Latest news about DermTech, Inc (DMTK) common stock and company :

Should Investors Consider Sight Sciences Stock?
11 Jan, 2022 FinancialContent

The company recently became publicly traded.

The Top Stocks These Investors Plan on Buying Soon
10 Jan, 2022 FinancialContent

The stock market is full of bargain buys at the moment.

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
07 Jan, 2022 FinancialContent

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:CVI) was changed from Peer Perform to ...

12 Health Care Stocks Moving In Monday's After-Market Session
03 Jan, 2022 FinancialContent

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 6.6% to $6.58 during Monday's after-market session. Today's trading volume for ...

Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
29 Dec, 2021 FinancialContent

These two stocks could provide life-changing returns in 10 years.

Advisors' Inner Circle Fund III Buys SPDR Biotech ETF, Scientific Games Corp, Silvergate ...
28 Dec, 2021 Yahoo! Finance

Investment company Advisors' Inner Circle Fund III (Current Portfolio) buys SPDR Biotech ETF, Scientific Games Corp, Silvergate Capital Corp, Boot Barn Holdings Inc, UMH Properties Inc, sells Squarespace Inc, Arena Pharmaceuticals Inc, Vimeo Inc, Singular Genomics Systems Inc, Inspire Medical Systems Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Advisors' Inner Circle Fund III.

The "Rule Breaker Investing" Podcast Looks Back at the Best of 2021
24 Dec, 2021 FinancialContent

This year has been one for the ages.

63 Biggest Movers From Friday
20 Dec, 2021 FinancialContent

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on ...

Royce Value Trust, Inc. Buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Sells EQT Corp, ...
17 Dec, 2021 Yahoo! Finance

Investment company Royce Value Trust, Inc. (Current Portfolio) buys Calix Inc, MaxCyte Inc, Dutch Bros Inc, Eagle Materials Inc, Scientific Games Corp, sells EQT Corp, SmileDirectClub Inc, , Hilton Grand Vacations Inc, Kulicke & Soffa Industries Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Royce Value Trust, Inc..

BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solution Lineup
15 Dec, 2021 Yahoo! Finance

BioIQ, Inc., ("BioIQ") an analytics-driven population health and testing platform company for top employers, health plans, and government agencies, and DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement to bring increased patient access to precision genomics. The DermTech Melanoma Test is now included in BioIQ's lineup of testing options for employee and member health programs. The program w

DermTech Enters Oversold Territory (DMTK)
13 Dec, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Why DermTech Still Has Ten-Bagger Potential
04 Dec, 2021 FinancialContent

Skin-cancer detection could lead to big returns for this stock.

Here's Why We're Not Too Worried About DermTech's (NASDAQ:DMTK) Cash Burn Situation
02 Dec, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

DermTech Unveils DermTech Stratum, an Expanded Translational Medicine Service Offering for Non-invasive Biomarker Analysis
29 Nov, 2021 FinancialContent

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the expansion and branding of its translational medicine service offering, DermTech Stratum™, which utilizes DermTech’s non-invasive technology and precision biomarker approaches to bring heightened precision and personalization to dermatologic disease diagnosis and treatment development. This broadened service offering leverages DermTech’s proprietary platform technology for biomarker analysis of RNA, DNA, protein and microbiome.

This Is the Main Problem With DermTech's Q3 Results
20 Nov, 2021 FinancialContent

Nothing major changed for the skin genomics company in Q3.

DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit
18 Nov, 2021 FinancialContent

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its session presentation, focused on non-invasive precision dermatology approaches, at the fifth annual Dermatology Drug Development Summit for Inflammatory Skin Diseases. Held in Boston this year, the Dermatology Drug Development Summit is a prestigious forum committed to overcoming significant R&D hurdles and sharing best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions.

Oversold Conditions For DermTech (DMTK)
17 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Got $50? 3 Roughed-Up Growth Stocks Set to Soar
17 Nov, 2021 FinancialContent

These stocks have grown quarterly sales 34%, 43%, and 140% year over year.

Analysts Anticipate XBI Will Reach $216
12 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $215.62 per unit.

Better Buy: 10x Genomics vs. DermTech
11 Nov, 2021 FinancialContent

Both companies offer disruptive new solutions in their niches of the healthcare space.

Noteworthy Wednesday Option Activity: DMTK, IRBT, VERI
10 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DermTech Inc (DMTK), where a total volume of 3,566 contracts has been traded thus far today, a contract volume which is representative of approximately 356,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 78.9% of DMTK's average daily trading volume over the past month, of 452,225 shares..

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
10 Nov, 2021 FinancialContent

Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market ...

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
10 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It's time to start another busy day of trading with a dive into the biggest pre-market stock movers for Wednesday. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

30 Stocks Moving in Wednesday's Pre-Market Session
10 Nov, 2021 FinancialContent

Gainers RenovoRx, Inc. (NASDAQ: RNXT) rose 113% to $11.50 in pre-market trading. The company, on Tuesday evening, made a ...

DermTech, Inc. (DMTK) Reports Q3 Loss, Lags Revenue Estimates
09 Nov, 2021 Yahoo! Finance

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.62% and -10.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech Reports Third Quarter 2021 Financial Results
09 Nov, 2021 FinancialContent

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results for the quarter ended September 30, 2021.

DermTech's Return On Capital Employed Overview
09 Nov, 2021 FinancialContent

DermTech (NASDAQ:DMTK) brought in sales totaling $3.12 million during Q2 according to data provided by Benzinga Pro. However, earnings ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
09 Nov, 2021 FinancialContent

Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The ...

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

DermTech, Inc (DMTK) is a NASDAQ Common Stock listed in , ,

970x250